Treatment Strategies in Relapsed Refractory Multiple Myeloma

Opinion
Video

Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.

Recent Videos
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
3 panelists
5 panelists
3 experts are featured in this series
3 panelists
Related Content
Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.

All Respond to BCMA/CD19 CAR T-Cell Therapy in NDMM Trials

Chris Ryan
December 19th 2025
Article

Based on phase 1 data, GC012F/AZD0120 may broaden therapeutic options for patients with newly diagnosed multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?

Tim Cortese
December 14th 2025
Article

Alan Pliskin and Mary Kay Yamamoto discuss their journey through multiple myeloma treatment, emphasizing the importance of knowledge, positivity, and quality of life.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

The 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.

Discontinuing Teclistamab Early Yields Comparable Efficacy vs Continuous Therapy in RRMM

Caroline Seymour
December 11th 2025
Article

The 6- and 12-month PFS rates were 76.4% and 68.2%, respectively, in patients with relapsed/refractory multiple myeloma who discontinued treatment with teclistamab early.

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

Tumor Burden Does Not Impact CRS Risk With Elranatamab Combo in Myeloma

Roman Fabbricatore
December 10th 2025
Article

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.